Vmbook Online ordering

Array Biopharma Inc

Array Biopharma Inc. (NASDAQ: ARRY) is a publicly traded biopharmaceutical company based in the United States. The company is focused on the development, manufacture, and commercialization of targeted small molecule medicines to treat patients afflicted with cancer and other high-burden diseases.

The company's lead product, BRAFTOVI® (encorafenib), in combination with MEKTOVI® (binimetinib), has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. Additionally, the company has a robust pipeline of investigational medicines in various stages of development, including candidates for the treatment of several types of cancer and other diseases.

Array Biopharma was founded in 1998 and is headquartered in Boulder, Colorado. The company employs around 400 people and its stock is listed on the NASDAQ stock exchange.

It's important to note that this information is for general purposes and the stock price, financial and business information could change over time. It's recommended to consult the company's official website, financial reports, sec filings and other relevant sources for the most recent information. Also, investing in stocks always carries risk, and it is advisable to consult a financial advisor before making any investment decisions.